Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Par-4 Down-regulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy Alvarez, James V. , Pan, Tien-chi , Ruth, Jason , Feng, Yi ... - - Cancer Cell - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009 Abstract - Primary Endpoint - Primary Analysis - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) Boudreau, A. , Yau, C. , Petrillo, L. , Stemke-Hale, K. , Mills, G. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context Campbell, Michael J. , Wolf, Denise , Mukhtar, Rita A. ... - - PLoS ONE - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633 Capelletti, M. , Wang, X. F. , Gu, L. , Graziano, S. L. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9633
High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance) Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - - Clin. Cancer Res. - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0337 , N98-32-52
Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657) Clark, Amy S , Chen, Jinbo , Kapoor, Shiv , Friedman, Claire ... - - Cancer Med - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance) Clarke, Jeffrey M. , Pang, Herbert , Starr, Mark D. , Hatch, Ace ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80303
Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657) Demichele, A. , Dunn, L. , Gimotty, P. , Livasy, C. , Perou, C. ... - ASCO - J Clin Oncol - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Comparison of community and central Her2 assessment on outcome of neoadjuvant chemotherapy in the I-SPY trial (CALGB 150007/150012, ACRIN 6657) Demichele, A. , Yau, C. , Zhu, J. , Wuhfkuhle, J. , Lenburg, M. E. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. DiGiovanna, Michael P , Stern, David F , Edgerton, Susan ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - C8541
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304 Edelman, Martin J. , Hodgson, Lydia , Rosenblatt, Paula Y. ... - - J Thorac Oncol - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150304
Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders Ellis, M. , Luo, J. , Tao, Y. , Hoog, J. , Snider, J. , DeSchryver, K. ... - - Cancer Research - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACOSOG-Z1031
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer Ellis, Matthew J , Lin, Li , Crowder, Robert , Tao, Yu , Hoog, Jeremy ... - - Breast Cancer Res Treat - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - ACOSOG-Z1031
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657 Esserman, L. J. , Berry, D. A. , Demichele, A. , Carey, L. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012 , ACRIN-6657
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY Trial (CALGB 150007/150012, ACRIN 6657) Esserman, L. J. , Perou, C. M. , Cheang, M. , Demichele, A. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Esserman, Laura J. , Berry, Donald A. , Cheang, Maggie C. U. ... - - Breast Cancer Res. Treat - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance) George, Daniel.J. , Halabi, Susan , Nixon, Andrew B. , Starr, Mark D. ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-90206
Sentinel node biopsy performed in the neoadjuvant setting for Breast Cancer: Results from the CALGB 150007 & 150012/ACRIN 6657 I-SPY TRIAL Gomez, R. , Zakhireh, J. , Moore, D. , Demichelle, A. , Przewoznik, J. ... - SABCS - Cancer Res. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Prognostic significance of molecular markers and clinical factors in stage IB non-small cell lung cancer (NSCLC): A laboratory companion study to CALGB 9633 Graziano, S. L. , Gu, L. , Wang, X. , Tatum, A. , Vollmer, R. T. ... - - J Thorac Oncol - 2007 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-159802 , CALGB-9633
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Haricharan, Svasti , Punturi, Nindo , Singh, Purba ... - - Cancer Discov - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - ACOSOG-Z1031
Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013 Harris, Lyndsay N. , Broadwater, Gloria , Abu-Khalaf, Maysa ... - - J. Clin. Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150013 , C8541
Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) Hatch, Ace J. , Sibley, Alexander B. , Starr, Mark D. ... - - Cancer Med - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80203
Genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer Hatzis, Christos , Pusztai, Lajos , Valero, Vicente ... - - JAMA - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
HER2 and response to paclitaxel in node-positive breast cancer. Hayes, Daniel F , Thor, Ann D , Dressler, Lynn G , Weaver, Donald ... - - N. Engl. J. Med. - 2007 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9344
Multivariate Analysis of Subtype and Gene Expression Signatures Predictive of Pathologic Complete Response (pCR) in Triple-Negative Breast Cancer (TNBC): CALGB 40603 (Alliance) Hoadley, Katherine A. , Hyslop, Terry , Fan, Cheng , Berry, Donald A. ... - SABCS - Cancer Res - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-40603
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-50103
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome Innocenti, Federico , Ou, Fang-Shu , Qu, Xueping , Zemla, Tyler J. ... - - J. Clin. Oncol - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405
Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance) Innocenti, Federico , Ou, Fang-Shu , Zemla, Tyler ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405
CALGB 150002: Correlation of HER-2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840: Paclitaxel (P) +/-T in HER-2(+) and (-) metastatic breast cancer (MBC) Kaufman, P. A. , Broadwater, G. , Lezon-Geyda, K. A. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - C150002
Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS Kim, Kyu-pyo , Parise, Robert A. , Holleran, Julianne L. ... - - J Pharm Biomed Anal - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - A031201
Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: results from two prospective cohorts and CALGB 89803 Alliance) trial Kosumi, Keisuke , Hamada, Tsuyoshi , Zhang, Sui , Liu, Li ... - - Eur. J. Cancer - 2019 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Correl Sci NOS - CALGB-89803
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-59804
Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival Landis, M. , Yau, C. , Neumeister, V. , Rimm, D. , Esserman, L. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012
p53 Expression in Node Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B (CALGB) 9344 Trial (159905) Lara, Jonathan F. , Thor, Ann D. , Dressler, Lynn G. ... - - Clin Cancer Res - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-159905 , CALGB-9344
Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147 Lee, A. , Shi, Q. , Pavey, E. , Sargent, D. J. , Alberts, S. R. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - ASCO GI - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0147
Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance) Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - - Pharmacogenet. Genomics - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0147
DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147) Lee, Adam M. , Shi, Qian , Pavey, Emily , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy trial: NCCTG N0147 (Alliance) Lee, Hee Eun , Shi, Qian , Foster, Nate , Chan, Emily , Gill, Sharlene ... - USCAP - Mod Pathol - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Impact of Consensus Molecular Subtyping (CMS) on overall survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P. ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P ... - - J. Clin. Oncol. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - A151425 , CALGB-80405
RANK expression in primary tumor tissue at the time of diagnosis correlates with risk of subsequent bone metastases in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657) Li, J. , Yau, C. , Campbell, M. , Park, J. W. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening Lin, C. , Moore, D. , Demichele, A. , Ollila, D. W. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes Liotta, L. , Pierobon, M. , Wulfkuhle, J. , Laird, J. , Livasy, C. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer Lips, Esther H. , Mukhtar, Rita A. , Yau, Christina ... - - Breast Cancer Res. Treat. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy Liu, M. , Pitcher, B. , Mardis, E. , Davies, S. , Snider, J. ... - AACR - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9741
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) Liu, Minetta C , Pitcher, Brandelyn N , Mardis, Elaine R ... - - NPJ Breast Cancer - 2016 Manuscript - Primary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-159905 , C9741
An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors Luo, Jingqin , Liu, Shuzhen , Leung, Samuel , Gru, Alejandro A. ... - - J Mol Diagn - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACOSOG-Z1031
Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 / NCCTG N063H (Alliance) Magbanua, Mark Jesus M. , Hendrix, Laura , Hyslop, Terry ... - SABCS - Cancer Res - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-40502 , NCCTG-N063H
Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance) Magbanua, Mark Jesus M. , Rugo, Hope S. , Wolf, Denise M. ... - - Clin. Cancer Res. - 2018 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Correl Sci NOS - CALGB-40502 , CALGB-40503
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response Magbanua, Mark Jesus M. , Wolf, Denise M. , Yau, Christina ... - - Breast Cancer Res - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Tumor SPARC Microenvironment Signature and Plasma Levels in a Phase II Trial of Unresectable Stage IV Melanoma Treated With nab-Paclitaxel and Carboplatin: A Translational Study of NCCTG Trial N057E Markovic, S. , Suman, V. , Treiu, V. , Liu, X. , Yeh, W. , Hwang, L. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N057E
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer Martin, M. , Prat, A. , Rodriguez-Lescure, A. , Caballero, R. ... - - Breast Cancer Res. Treat. - 2013 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Correl Sci NOS - CALGB-9342 , CALGB-9840
Central Pathology Laboratory Review of HER2 and ER in Early Breast Cancer: An ALTTO Trial [BIG 2-06 / NCCTG N063D (Alliance)] Ring Study McCullough, Ann E. , Dell'Orto, Patrizia , Reinholz, Monica M. ... - - Breast Cancer Res. Treat. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N063D
A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. Mcwilliams, R. R. , Mahoney, M. R. , Sargent, D. J. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers Miller, Christopher A. , Gindin, Yevgeniy , Lu, Charles ... - - Nat Commun - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - ACOSOG-Z1031
Lobular breast cancer and NAC: Combined results from the NKI and I-SPY 1 trial Mukhtar, R. A. , Lips, E. , Wesseling, J. , Livasy, C. , Yau, C. ... - - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
PCNA+ tumor associated macrophages are associated with M1 and M2 gene expression, and confer poor prognosis in the absence of anti-tumor immune environment Mukhtar, R. A. , Wolf, D. , Tandon, V. , Zhu, J. , Lenburg, M. ... - - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741 Ng, Kimmie , Sargent, Daniel J. , Goldberg, Richard M. ... - - J Clin Oncol - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N9741
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) Niedzwiecki, Donna , Frankel, Wendy L. , Venook, Alan P. , Ye, Xing ... - - J. Clin. Oncol - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150705 , C9581
Intrinsic subtype and response to paclitaxel in CALGB 9344 tissue microarrays Nielsen, T. O. , Jewell, S. D. , Thor, A. D. , Gao, D. , Perou, C. M. ... - ASCO Breast - Breast Cancer Symposium - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-159905 , C9344
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer Nielsen, Torsten O. , Parker, Joel S , Leung, Samuel , Voduc, David ... - - Clin Cancer Res - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-159905 , CALGB-9344
Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405 Nixon, Andrew B. , Sibley, Alexander B. , Hatch, Ace J. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status Rego, R L , Foster, N R , Smyrk, T C , Le, M , O'Connell, M J ... - - Br J Cancer - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-894651 , NCCTG-91-46-53
The concordance between NCCTGs and NSABPs C-myc FISH assays Reinholz, M. , Dueck, A. , Lingle, W. , Ziegler, A. , Wiktor, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N9831
EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial. Rimm, D. L. , Ballman, K. , Cheng, H. , Vassilakopoulou, M. , Chen, B. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N9831
Identification of Potential Prognostic Biomarkers in Patients with Untreated, Advanced Pancreatic Cancer from a Phase III Trial (CALGB 80303) Roberts, Andrew S. , Campa, Michael J. , Gottlin, Elizabeth B. ... - - Cancer - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80303
Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens Salama, A. K. , Kratzke, R. A. , Richards, W. , Pang, H. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Preliminary Analysis - Correl Sci NOS - CALGB-150607
An Interim Analysis Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens Salgia, R. , Nallasura, V. , Pang, H. , Rolle, C. , Richards, W. ... - Chicago MSTO - Clin. Cancer Res. - 2012 Abstract - Secondary Endpoint - Preliminary Analysis - Correl Sci NOS - CALGB-150607
High proliferation by the MCL35 assay is associated with inferior outcomes in patients treated with intensive regimens – a correlative study from the Alliance 50403 trial. Scott, David W. , Pitcher, Brandelyn , Liu, Yi Tian , Boyle, Merrill ... - ICML - Hematol Oncol - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-50403
Association of RAS mutations with race in metastatic colorectal cancer CALGB 80405 (Alliance) Sehdev, Amikar , Niedzwiecki, Donna , Venook, Alan P. ... - ASCO GI - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80405
Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147 Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147. Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen J. ... - - JAMA Oncol - 2017 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Correl Sci NOS - NCCTG-N0147
Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ASCO GI - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX (Alliance N0147) Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne , Heying, Erica ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Shi, Qian , Lee, Hee Eun , Foster, Nathan R. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance) Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)]. Sinicrope, Frank A. , Shi, Qian , Thibodeau, Stephen N. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0147
Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance) Sinicrope, Frank A. , Smyrk, Thomas C. , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. Sinicrope, Frank A. , Yoon, Harry H. , Mahoney, Michelle R. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0147
A low intraepithelial effector (CD3+):regulatory (FoxP3+) T-cell ratio predicts adverse outcome of human colon carcinoma Sinicrope, Frank A , Rego, Rafaela L , Ansell, Stephen M ... - - Gastroenterology - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0442
Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401) Sohani, Aliyah R. , Pitcher, Brandy , Chadburn, Amy , Said, Jonathan ... - ASH - Blood - 2015 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Correl Sci NOS - CALGB-50401 , CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901
Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer (Alliance) Tanioka, Maki , Parker, Joel S , Henry, Lynn N , Tolaney, Sara ... - SABCS - Cancer Res - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-40601
Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) Wilcox, Ryan E. , Shi, Qian , Sinicrope, Frank A. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N0147
Patient-specific integrative pathway analysis using PARADIGM identifies key activities in I-SPY 1 breast cancer patients (CALGB 150007/150012; ACRIN 6657) Wolf, D. , Yau, C. , Benz, S. , Vaske, C. , Stuart, J. , Roy, R. ... - SABCS - Cancer Res. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - ACRIN-6657 , CALGB-150007
Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Wolf, D. , Yau, C. , Magbanua, M. , Boudreau, A. , Davis, S. , Haqq, C. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012
Discovery of a new phosphoHER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping Wulfkuhle, J. , Pierobon, M. , Laird, J. , Espina, V. , Liotta, L. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2– tumors Wulfkuhle, J. , Yau, C. , Gallagher, R. , Wolf, D. , Calvert, V. ... - SABCS - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping Wulfkuhle, Julia D. , Berg, Daniela , Wolff, Claudia , Langer, Rupert ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Inter-tumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch repair-deficient colon cancers: implications for prognosis Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - - Clin. Cancer Res. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance) Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - - JAMA Oncol - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N0147
